.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Biosimilars

The AJMC^® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Optimizing the Transition to Biosimilars: Considerations for Payers

Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the use of biosimilars at their organizations and what payers should be thinking about when considering biosimilar transitions.

Dr Sonia Oskouei on Managed Care’s Impact After Rollout of Adalimumab Biosimilars

May 16th 2022, 1:05pm

Video

While 2023 is a big year with at least 7 adalimumab biosimilars expected to come to market, 2024 will be even more important because all the products will be on the market and formulary decisions can be made, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.

Managed Care Has a Key Role in Biosimilar Adoption, Says Cardinal's Oskouei

May 12th 2022, 1:17pm

Article

Biosimilar adoption can be accelerated or stymied depending on actions taken by the managed care space, explained Sonia Oskouei, PharmD, vice president, biosimilars, Cardinal Health, during a session at Asembia’s Specialty Pharmacy Summit.

IQVIA’s Doug Long: Adalimumab Biosimilars Provide More Opportunity for Price Discounts

May 10th 2022, 4:52pm

Video

The impact that the adalimumab biosimilars will have in 2023 is going to depend on when they all get to market, said Doug Long, MBA, vice president, industry relations, IQVIA.

340B, Biosimilars, and More in the Future of Specialty Pharmacy

May 4th 2022, 1:08pm

Article

Adam Fein, PhD, of Drug Channels Institute, and Doug Long of IQVIA discussed trends in the specialty pharmacy market in the United States.

Gottlieb, Fein Discuss COVID-19, Accelerated Approvals, and Drug Pricing at Asembia 2022

May 3rd 2022, 6:41pm

Article

Scott Gottlieb, MD, and Adam Fein, PhD, discussed potential fallout of the FDA Aduhelm approval and lessons learned from the COVID-19 pandemic.

Biosimilar Education Needed for Pediatric Patients With IBD and Caregivers

April 30th 2022, 5:20pm

Article

Not only did a majority of each group say they hadn’t heard of biosimilars, but those who had heard of them had negative perceptions.

Dr Gillian Woollett Highlights International Markets With Successful Biosimilar Adoption

April 29th 2022, 4:20pm

Video

Gillian Woollett, MA, Dphil, vice president and head of regulatory strategy and policy at Samsung Bioepis, gives insight into what international markets the United States could look to as examples of good biosimilar adoption.

Ryan Haumschild, PharmD, Explains How Emory Healthcare Will Address the Influx of Humira Biosimilars in 2023

April 23rd 2022, 11:00am

Video

Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives insight into how his practice will handle the influx of at least 7 adalimumab biosimilars referencing Humira that are expected to enter the market in 2023.

Biosimilars Still Used Significantly Less Than Reference Products in Medicare Part D

April 21st 2022, 5:32pm

Article

Increased uptake of biosimilars on par with the utilization rates of filgrastim biosimilars could have saved Medicare Part D $84 million in 2019.

FDA Approves Third Bevacizumab Biosimilar

April 15th 2022, 7:24pm

Article

Alymsys from Amneal Pharmaceuticals and mAbxience is the third biosimilar referencing Avastin approved in the United States and the second of 3 biosimilar approvals Amneal expects in 2022.